Tibotec Pharmaceuticals Ltd.
68Patents
41Active
68Granted
47Portfolio score
Filing activity: Feb 14, 2002 → Jun 21, 2012 · 36 expiring within 5 years
Most-cited patents
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US7531548B2 | HIV inhibiting 5-carbo- or heterocyclic substituted pyrimidines | Chemistry; Metallurgy | 55 | Expired |
| US8022077B2 | Pyrido[2,3-d]pyrimidines useful as HCV inhibitors, and methods for the preparation thereof | Human Necessities | 29 | Expired |
| US8030318B2 | Fused bicyclic inhibitors of HCV | Human Necessities | 28 | Expired |
| US8148399B2 | Macrocyclic inhibitors of hepatitis C virus | Emerging Cross-Sectional Technologies | 20 | Active |
| US7700645B2 | Pseudopolymorphic forms of a HIV protease inhibitor | Human Necessities | 19 | Active |
| US8349869B2 | Macrocylic inhibitors of hepatitis C virus | Emerging Cross-Sectional Technologies | 12 | Active |
| US7659245B2 | Macrocylic inhibitors of hepatitis C virus | Chemistry; Metallurgy | 12 | Active |
| US8153640B2 | HIV inhibiting bicyclic pyrimdine derivatives | Chemistry; Metallurgy | 12 | Active |
| US7442705B2 | HIV replication inhibiting pyrimidines and triazines | Chemistry; Metallurgy | 11 | Expired |
| US6649651B1 | Hexahydrofuro[2,3-B]furan-3-yl-n{3[(1,3-benzodioxol-5-ylsulfonyl)(isobutyl)amino]-1-benzyl-2-hydroxypropyl}carbamate as retroviral protease inhibitor | Human Necessities | 9 | Expired |
| US7989471B2 | Macrocyclic inhibitors of hepatitis C virus | Chemistry; Metallurgy | 9 | Active |
| US8153800B2 | Macrocyclic inhibitors of hepatitis C virus | Emerging Cross-Sectional Technologies | 7 | Active |
| US8012939B2 | Macrocyclic inhibitors of hepatitis C virus | Chemistry; Metallurgy | 7 | Active |
| US7199148B2 | Broadspectrum substituted oxindole sulfonamide HIV protease inhibitors | Chemistry; Metallurgy | 6 | Expired |
| US7666834B2 | Macrocyclic inhibitors of hepatitis C virus | Chemistry; Metallurgy | 6 | Active |
| US7935710B2 | Microbicidal pyrimidine or triazine for preventing sexual HIV transmission | Human Necessities | 6 | Expired |
| US7449463B2 | Morpholinyl containing benzimidazoles as inhibitors of respiratory syncytial virus replication | Chemistry; Metallurgy | 4 | Expired |
| US8426434B2 | Crystalline form of 4-[[4-[[4-(2-Cyanoethenyl)-2,6-dimethylphenyl]-amino]-2-pyrimidinyl]amino]benzonitrile | Human Necessities | 4 | Active |
| US7465727B2 | (1,10B-dihydro-2-(aminoalkyl-phenyl)-5H-pyrazolo[1,5-c][1,3]Benzoxazin-5-yl)phenyl methanone derivatives as HIV viral replication inhibitors | Human Necessities | 3 | Expired |
| US7157495B2 | Hexahydrofuro[2,3-B]furan-3-YL-N-{3-[(1,3-benzodioxol-5-ylsulfonyl)(isobutyl)amino]-1-benzyl-2-hydroxypropyl}carbamate as retroviral protease inhibitor | Human Necessities | 3 | Expired |
| US8034835B2 | 1-[[2-amino-3-(substituted alkyl)-3H-benzimidazolyl[methyl]-3-substituted-1,3-dihydro-benzoimidazol-2-ones and structural analogs | Chemistry; Metallurgy | 3 | Active |
| US7126015B2 | Method for the preparation of hexahydro-furo-[2,3-b]furan-3-ol | Emerging Cross-Sectional Technologies | 3 | Expired |
| US7217506B2 | Mutational profiles in HIV-1 protease correlated with phenotypic protease inhibitor resistance | Physics | 3 | Expired |
| US8036861B2 | Method and means for determining the replication rate of a viral population | Emerging Cross-Sectional Technologies | 2 | Active |
| US7087373B2 | Methods for determining plasma free drug concentration by direct measurement of binding affinity of protease inhibitors to plasma proteins | Physics | 2 | Expired |
Source: USPTO / EPO open patent data. Counts and citation impact are objective bibliographic measures.